Core Net Debt from 2010 to 2026

CLB Stock

USD 19.54 0.10 0.51%

Core Laboratories' Net Debt is increasing over the years with very volatile fluctuation. Overall, Net Debt is expected to go to about 186.6 M this year. Net Debt is the total debt of Core Laboratories NV minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1995-09-30

Previous Quarter

147.4 M

Current Value

141.5 M

Quarterly Volatility

105.1 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Core Laboratories financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Core Laboratories' main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.7 M, Interest Expense of 10.2 M or Selling General Administrative of 34.9 M, as well as many indicators such as Price To Sales Ratio of 2.65, Dividend Yield of 0.002 or PTB Ratio of 2.75. Core financial statements analysis is a perfect complement when working with Core Laboratories Valuation or Volatility modules.

Build AI portfolio with Core Stock

Check out the analysis of Core Laboratories Correlation against competitors.

Analyzing Core Laboratories's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Core Laboratories's current valuation and future prospects.

Latest Core Laboratories' Net Debt Growth Pattern

Below is the plot of the Net Debt of Core Laboratories NV over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Core Laboratories' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Core Laboratories' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Core Net Debt Regression Statistics

	Arithmetic Mean	232,450,208
	Geometric Mean	197,444,176
	Coefficient Of Variation	39.10
	Mean Deviation	64,586,417
	Median	212,589,000
	Standard Deviation	90,882,608
	Sample Variance	8259.6T
	Range	398.2M
	R-Value	0.02
	Mean Square Error	8806.5T
	R-Squared	0.0004
	Significance	0.94
	Slope	374,888
	Total Sum of Squares	132154.4T

Core Net Debt History

	2026	186.6 M
	2025	185.1 M
	2024	161 M
	2023	200.3 M
	2022	207 M
	2021	232.6 M
	2020	313.2 M

Other Fundumenentals of Core Laboratories

Net Debt To E B I T D A

Core Laboratories Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Treasury Stock	Net Tangible Assets	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Long Term Investments	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.39	0.73	0.5	0.7	0.73	0.85	0.82	0.35	0.33	0.41	0.55	0.54	0.49	0.26	-0.28	-0.38	0.4	0.18	0.38	0.01	0.23	-0.03	0.16	0.18	-0.08
Total Stockholder Equity	0.39		-0.3	0.07	0.41	0.28	-0.15	0.38	0.0	-0.27	-0.31	-0.52	0.48	0.07	-0.31	0.42	0.57	0.62	-0.78	0.63	-0.71	0.62	0.5	-0.05	0.68	-0.64
Net Debt	0.73	-0.3		0.33	0.29	0.44	0.96	0.48	0.39	0.57	0.55	0.9	0.23	0.33	0.43	-0.47	-0.72	0.06	0.72	0.01	0.47	-0.08	-0.4	0.22	-0.25	0.3
Retained Earnings	0.5	0.07	0.33		0.77	0.93	0.51	0.84	-0.16	0.19	0.39	0.51	0.1	0.51	0.41	-0.85	-0.38	-0.21	0.37	-0.18	0.43	-0.53	-0.09	0.28	-0.05	0.14
Accounts Payable	0.7	0.41	0.29	0.77		0.91	0.52	0.91	-0.13	0.07	0.51	0.32	0.29	0.61	0.28	-0.47	-0.22	0.04	0.06	0.07	0.08	-0.19	-0.02	0.03	0.11	0.08
Net Receivables	0.73	0.28	0.44	0.93	0.91		0.64	0.97	-0.1	0.16	0.43	0.5	0.32	0.55	0.33	-0.69	-0.36	-0.05	0.25	0.05	0.31	-0.28	-0.01	0.2	0.09	0.02
Total Liab	0.85	-0.15	0.96	0.51	0.52	0.64		0.67	0.38	0.51	0.63	0.89	0.3	0.49	0.46	-0.56	-0.73	0.08	0.64	0.04	0.42	-0.12	-0.32	0.21	-0.2	0.28
Total Current Assets	0.82	0.38	0.48	0.84	0.91	0.97	0.67		0.0	0.08	0.36	0.47	0.46	0.51	0.21	-0.58	-0.31	0.05	0.17	0.22	0.23	-0.09	0.09	0.13	0.2	-0.11
Short Term Debt	0.35	0.0	0.39	-0.16	-0.13	-0.1	0.38	0.0		0.07	-0.03	0.27	0.42	0.08	0.0	0.09	-0.27	0.39	0.07	0.44	-0.07	0.44	0.1	-0.15	0.1	-0.11
Intangible Assets	0.33	-0.27	0.57	0.19	0.07	0.16	0.51	0.08	0.07		0.52	0.57	-0.31	0.38	0.82	-0.3	-0.49	0.19	0.64	-0.39	0.15	-0.35	-0.75	0.6	-0.26	0.55
Common Stock	0.41	-0.31	0.55	0.39	0.51	0.43	0.63	0.36	-0.03	0.52		0.59	-0.1	0.52	0.55	-0.5	-0.67	-0.06	0.53	-0.42	0.25	-0.54	-0.53	-0.02	-0.65	0.82
Long Term Debt	0.55	-0.52	0.9	0.51	0.32	0.5	0.89	0.47	0.27	0.57	0.59		-0.01	0.48	0.62	-0.71	-0.85	-0.25	0.91	-0.27	0.7	-0.42	-0.5	0.3	-0.33	0.46
Property Plant Equipment	0.54	0.48	0.23	0.1	0.29	0.32	0.3	0.46	0.42	-0.31	-0.1	-0.01		-0.14	-0.46	0.01	-0.03	0.32	-0.3	0.88	-0.05	0.58	0.64	-0.44	0.45	-0.46
Current Deferred Revenue	0.49	0.07	0.33	0.51	0.61	0.55	0.49	0.51	0.08	0.38	0.52	0.48	-0.14		0.74	-0.37	-0.55	-0.1	0.32	-0.31	0.14	-0.32	-0.23	0.43	0.02	0.27
Good Will	0.26	-0.31	0.43	0.41	0.28	0.33	0.46	0.21	0.0	0.82	0.55	0.62	-0.46	0.74		-0.49	-0.62	-0.14	0.68	-0.56	0.3	-0.58	-0.7	0.67	-0.19	0.56
Treasury Stock	-0.28	0.42	-0.47	-0.85	-0.47	-0.69	-0.56	-0.58	0.09	-0.3	-0.5	-0.71	0.01	-0.37	-0.49		0.67	0.47	-0.72	0.36	-0.77	0.73	0.26	-0.26	0.33	-0.4
Net Tangible Assets	-0.38	0.57	-0.72	-0.38	-0.22	-0.36	-0.73	-0.31	-0.27	-0.49	-0.67	-0.85	-0.03	-0.55	-0.62	0.67		0.33	-0.81	0.29	-0.65	0.48	0.36	-0.2	0.41	-0.56
Deferred Long Term Liab	0.4	0.62	0.06	-0.21	0.04	-0.05	0.08	0.05	0.39	0.19	-0.06	-0.25	0.32	-0.1	-0.14	0.47	0.33		-0.44	0.48	-0.76	0.61	0.07	-0.04	0.23	-0.22
Long Term Debt Total	0.18	-0.78	0.72	0.37	0.06	0.25	0.64	0.17	0.07	0.64	0.53	0.91	-0.3	0.32	0.68	-0.72	-0.81	-0.44		-0.53	0.8	-0.64	-0.64	0.38	-0.48	0.61
Capital Surpluse	0.38	0.63	0.01	-0.18	0.07	0.05	0.04	0.22	0.44	-0.39	-0.42	-0.27	0.88	-0.31	-0.56	0.36	0.29	0.48	-0.53		-0.34	0.83	0.65	-0.39	0.63	-0.67
Short Long Term Debt	0.01	-0.71	0.47	0.43	0.08	0.31	0.42	0.23	-0.07	0.15	0.25	0.7	-0.05	0.14	0.3	-0.77	-0.65	-0.76	0.8	-0.34		-0.59	-0.2	0.13	-0.29	0.3
Long Term Investments	0.23	0.62	-0.08	-0.53	-0.19	-0.28	-0.12	-0.09	0.44	-0.35	-0.54	-0.42	0.58	-0.32	-0.58	0.73	0.48	0.61	-0.64	0.83	-0.59		0.56	-0.24	0.62	-0.72
Cash And Equivalents	-0.03	0.5	-0.4	-0.09	-0.02	-0.01	-0.32	0.09	0.1	-0.75	-0.53	-0.5	0.64	-0.23	-0.7	0.26	0.36	0.07	-0.64	0.65	-0.2	0.56		-0.43	0.54	-0.69
Net Invested Capital	0.16	-0.05	0.22	0.28	0.03	0.2	0.21	0.13	-0.15	0.6	-0.02	0.3	-0.44	0.43	0.67	-0.26	-0.2	-0.04	0.38	-0.39	0.13	-0.24	-0.43		0.16	-0.06
Net Working Capital	0.18	0.68	-0.25	-0.05	0.11	0.09	-0.2	0.2	0.1	-0.26	-0.65	-0.33	0.45	0.02	-0.19	0.33	0.41	0.23	-0.48	0.63	-0.29	0.62	0.54	0.16		-0.81
Capital Stock	-0.08	-0.64	0.3	0.14	0.08	0.02	0.28	-0.11	-0.11	0.55	0.82	0.46	-0.46	0.27	0.56	-0.4	-0.56	-0.22	0.61	-0.67	0.3	-0.72	-0.69	-0.06	-0.81

Click cells to compare fundamentals

About Core Laboratories Financial Statements

Core Laboratories stakeholders use historical fundamental indicators, such as Core Laboratories' Net Debt, to determine how well the company is positioned to perform in the future. Although Core Laboratories investors may analyze each financial statement separately, they are all interrelated. For example, changes in Core Laboratories' assets and liabilities are reflected in the revenues and expenses on Core Laboratories' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Core Laboratories NV. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	185.1 M	186.6 M
Net Debt To EBITDA	1.98	1.31

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VGIAX	Vanguard Growth And
XAR	SPDR SP Aerospace
XAR	SPDR SP Aerospace

When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:

How To Invest In Core

Details

Is Core Stock a good investment?

Details

What is Core Laboratories' Net Worth?

Details

Largest Oil & Gas Equipment & Services Companies

View

Largest Energy Companies

View

Check out the analysis of Core Laboratories Correlation against competitors.

You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. Projected growth potential of Core fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Core Laboratories assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Quarterly Earnings Growth

0.2

Dividend Share

0.04

Earnings Share

0.68

Revenue Per Share

11.096

Quarterly Revenue Growth

0.001

The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Core Laboratories' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Core Laboratories should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Core Laboratories' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Core Net Debt from 2010 to 2026

Latest Core Laboratories' Net Debt Growth Pattern

Core Net Debt Regression Statistics

Core Net Debt History

Other Fundumenentals of Core Laboratories

Core Laboratories Net Debt component correlations

About Core Laboratories Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY